Gapping up
In reaction to earnings/guidance:
- RLGT +13.5%, DBI +8.6%, DAO +5.7%, AZRE +5%, NTES +2.5%, NDSN +1.8%, .
Other news:
- ACIU +58.8% (announces first positive cognitive results for a tau-targeting monoclonal antibody in alzheimer's disease)
- SPOK +21.3% (Spok confirms Acacia Research (ACTG) proposal to acquire co for $10.75 per share)
- APPS +8.6% (to join S&P MidCap 400)
- GLPG +7% (CEO to retire)
- THS +5.5% (will move from S&P MidCap 400 to S&P SmallCap 600)
- PFGC +4.5% (to join S&P MidCap 400)
- MRBK +4.1% (increases share repurchase authorization up to $20 mln)
- LGND +3.9% (will move from S&P MidCap 400 to S&P SmallCap 600; also Ligand partner receives approval for zimberelimab in China)
- AMRN +1.6% (reports overview of latest clinical research evaluating VASCEPA/VAZKEPA and eicosapentaenoic acid Presented at ESC Congress 2021)
- TLIS +1.4% (CEO departs)
- NVAX +1% (issues statement on CDC guidance update for COVID-19 clinical trial participants)
Analyst comments:
- FNKO +4.5% (upgraded to Buy from Hold at Jefferies)
- BXS +2.7% (upgraded to Strong Buy from Outperform at Raymond James)
- ADS +2.6% (upgraded to Buy from Neutral at BofA Securities)
- CADE +1.6% (upgraded to Strong Buy from Outperform at Raymond James)
- TXT +1.6% (upgraded to Outperform from Market Perform at Cowen)